The dates for Life Science Innovation Northwest (LSINW) 2012 have been set for July 11-12, 2012 at the Washington State Convention Center. Chris E. Rivera, President, Washington Biotechnology & Biomedical Association (WBBA) made the announcement in conjunction with releasing the agenda for LSINW. This year’s conference will be an expansion of last year’s hugely successful conference. In addition to delegations expected from fourteen countries outside of the U.S., there will be six panels and 80 presentations by public and private companies, and non-profit and research organizations specializing in medical technology, diagnostics, therapeutic innovations, and cutting-edge developments in global health from Washington, Oregon, Montana, Idaho and British Columbia. With the expanded agenda and expected increase in attendance, LSINW will continue to be the Northwest’s preeminent life science conference.
“We’ve moved LSINW from March to July this year to coincide with the Next 50, the six month celebration of the 50th anniversary of the Seattle World’s Fair,” said Rivera. “Moving the conference date to July will also give our conference attendees the opportunity to have their family and friends visit Seattle during one of the most pleasant times of the year.” Rivera added, “We are also very pleased to once again partner with Burrill & Company to host the conference and we look forward to Steve Burrill’s compelling discussion of the latest in the economic and development trends in the industry.”
“We are delighted to be associated with the WBBA to stage this important event,” said G. Steven Burrill, CEO, Burrill & Company, a diversified global financial services firm focused on the life sciences industry. “The Pacific Northwest is a vibrant hub for biotechnology and life sciences innovation and these sectors are rapidly evolving as major economic drivers for the region. The conference will be a great opportunity to discover and interact with this community firsthand.”
G. Steven Burrill, Founder and CEO of Burrill & Company, has been involved in the growth and prosperity of the biotechnology industry for more than 40 years. He is an internationally recognized spokesperson and author for the life science and high technology industries. An early pioneer, Mr. Burrill is one of the original architects of the industry and is one of its most avid and sustained developers. He currently serves on the Boards of Directors of eight companies. Prior to founding Burrill & Company in 1994, Mr. Burrill spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, he was recognized as the biotech investment visionary of the year by the prestigious Scientific American magazine.
Rivera promised an exciting announcement later in the month regarding this year’s conference opening keynote speaker. Last year’s keynote was James C. Greenwood, President and CEO of the Biotechnology Industry Organization (BIO).
The Pacific Northwest has emerged as one of the world’s most innovative and important life science sectors. Now in its twelfth year, LSINW is expanding its reach to attract more investment and partnering representatives from outside the United States and is expecting participation from delegations from Asia, India, Australia, Scandinavia, Canada, France, Germany, and the Middle East. These delegations provide opportunities to explore financial and strategic partnerships and investments with companies, research institutions and non-profit organizations that attend and present at the conference.
About LSINW 2012
Life Science Innovation Northwest 2012 is presented by The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company. For more information on the LSINW 2012 conference, please visit www.washbio.org.
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington state. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: supporting breakthrough discoveries that lead to better health solutions. Learn more about the WBBA at www.washbio.org.
About Burrill & Company
Burrill & Company has established unrivaled access and visibility in the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking and media. A unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. (www.burrillandco.com).Business Wire
Last updated on: 03/04/2012
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.